CompletedNot Applicable

Long-term Safety Follow-up Study of Patients Having Received HepaStem (SAF001)

Belgium9 participantsStarted 2013-03

Plain-language summary

The purpose of this study is to assess the long-term safety follow-up of patients having been treated with HepaStem.

Who can participate

Age range23 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Main Inclusion Criteria: \- Subject having received HepaStem during a former interventional clinical study and who have terminated their participation in that study. Exclusion Criteria: \- Subject has received mature liver cells, stem cells transplantation other than HepaStem, or organ liver transplant.

What they're measuring

Characterisation of the long term safety profile of HepaStem therapy.

Timeframe: 4 years

Trial details

NCT IDNCT02051049

SponsorCellaion SA

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2018-04

View on ClinicalTrials.gov More Urea Cycle Disorders trials